Novo Nordisk, Eli Lilly
Digest more
Early results of Eli Lilly’s next generation of weight loss drugs appear to show promise, possibly leading to even faster weight loss and added health benefits.
The Trump administration on Thursday rolled out a much-anticipated deal with drugmakers Eli Lilly and Novo Nordisk that aims to deliver lower prices for their popular GLP-1 drugs to certain Medicare and Medicaid beneficiaries and to users of TrumpRx.
Eli Lilly and Novo Nordisk have become the latest pharma giants to strike price-reduction deals with the White House, agreeing to sell their weight loss drugs at cut-rate prices to patients in the U.S.
Eli Lilly shares are trading higher on Monday. The pharmaceutical giant announced a significant European manufacturing expansion.
Eli Lilly is partnering with Walmart to offer Zepbound through its direct-to-consumer program, making the popular medication more accessible nationwide.
U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, revenue from the diabetes drug Mounjaro, which has been on the market longer, has doubled, to $6.52 billion, thanks to growth outside the U.S.
The Michigan Supreme Court heard oral arguments Wednesday in the state attorney general’s case against insulin-maker Eli Lilly and Company.
Drug company Eli Lilly and NVIDIA announced a new partnership to build a supercomputer for drug research. Drug manufacturer Eli Lilly and NVIDIA have announced a partnership to build out an AI supercomputer for pharmaceutical research and development.
Food and Drug Administration to approve its experimental oral obesity drug, orforglipron, by March 2026, its chief executive said on Thursday. (Reporting by Kamal Choudhury in Bengaluru; Editing by Shilpi Majumdar).
Eli Lilly is expanding its Kenosha County campus with plans to construct six new buildings adjacent to the former Nexus Pharmaceuticals site.
Eli Lilly and Company (NYSE:LLY) develops medicines for diabetes, obesity, cancer, autoimmune disorders, and neurological conditions.
Feedback